Creative Medical (CELZ) Technology announced the completion of patient enrollment in its FDA-cleared ADAPT clinical trial evaluating CELZ-201, the Company’s proprietary perinatal tissue-derived cell therapy for the treatment of chronic lower back pain associated with degenerative disc disease. Enrollment completion follows a previously announced positive independent Data Safety Monitoring Board safety review, which confirmed that CELZ-201 demonstrated a favorable safety profile with no significant adverse events and supported continued advancement of the trial.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELZ:
- Creative Medical announces WHO approval of olastrocel as INN for CELZ-201
- Creative Medical files to sell 2.79M shares of common stock for holders
- Creative Medical Technology Approves Executive Bonuses
- Creative Medical Technology’s New Warrant Agreements Announced
- Creative Medical launches Biodefense Inc. Veterans Initiative